As a result, this impairs the activation of antigen-specific cytotoxic T lymphocyte (CTL) responses and hinders the differentiation of CD4+ T cells into anti-inflammatory Th1 cells, ultimately facilitating promoting tumor progression 38-39. The gene discussed is CD4; the disease is neoplasm.